Success Metrics

Active Trials

2(50%)

Phase Distribution

Ph phase_1

25%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Other(1)

Detailed Status

Active, not recruiting2

unknown1

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

active_not_recruiting250%

unknown125%

enrolling_by_invitation125%

Recent Activity

2 active trials

Showing 4 of 4

enrolling_by_invitation

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

NCT07527975

active_not_recruitingphase_2

Gene Therapy for Fanconi Anemia, Complementation Group A

NCT04248439

active_not_recruitingphase_2

Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

NCT04069533

unknownphase_1

A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

NCT03814408

Clinical Trials (4)

Showing 4 of 4 trials

NCT07527975

Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102

Enrolling By Invitation

NCT04248439Phase 2

Gene Therapy for Fanconi Anemia, Complementation Group A

Active Not Recruiting

NCT04069533Phase 2

Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Active Not Recruiting

NCT03814408Phase 1

A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Unknown

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4